Genesis IBRC India Ltd
NSE: BSE: 514336
₹93.22
(4.92%)
Mon, 16 Mar 2026, 03:20 am
Market Cap0
PE Ratio0
Dividend0
Producer Manufacturing
Miscellaneous Manufacturing
24.5KGenesis IBRC India Analysis
dividend
- Unable to evaluate Genesis IBRC India's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Genesis IBRC India's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Genesis IBRC India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Genesis IBRC India has no debt, it does not need to be covered by operating cash flow.
- Genesis IBRC India has no debt, it does not need to be covered by short term assets.
- Genesis IBRC India has no long term commitments.
- Genesis IBRC India currently has no debt however we can't compare to 5 years ago as we have no data for that period.
- Genesis IBRC India has no debt, therefore coverage of interest payments is not a concern.
- Genesis IBRC India has no debt.
- Low level of unsold assets.
- Genesis IBRC India has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.9% each year.
- Genesis IBRC India has less than a year of cash runway based on current free cash flow.
management
- The average tenure for the Genesis IBRC India board of directors is less than 3 years, this suggests a new board.
misc
- Genesis IBRC India is not covered by any analysts.
past
- Unable to compare Genesis IBRC India's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Genesis IBRC India does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- It is difficult to establish if Genesis IBRC India has efficiently used its assets last year compared to the IN Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Genesis IBRC India improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Genesis IBRC India has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Genesis IBRC India's 1-year growth to the Asia Biotechs industry average as it is not currently profitable.
value
- Genesis IBRC India is good value based on assets compared to the IN Biotechs industry average.
- Genesis IBRC India is loss making, we can't compare its value to the IN Biotechs industry average.
- Genesis IBRC India is loss making, we can't compare the value of its earnings to the India market.
- BSE:514336 is flat (0%) underperforming the Biotechs industry which returned 18.2% over the past month.
- BSE:514336 is flat (0%) underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800